EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia

Christie M Ballantyne, Laura Gellis, Jean-Claude Tardif, Puja Banka, Ann Marie Navar, Emil Andreas Asprusten, Russell Scott, Erik S G Stroes, Samar Froman, Geraldine Mendizabal, Fan Wang, Alberico L Catapano

JAMA · 13.01.2026 · 335 (2) · 129

DOI: 10.1001/jama.2025.20620 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 13.01.2026. Verfasst von Christie M Ballantyne und 11 weiteren Autor:innen. Beteiligte Einrichtung: Texas Heart Institute, Baylor College of Medicine, Houston, Texas. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Hyperlipoproteinemia Type II, PCSK9 Inhibitors. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Persons with heterozygous familial hypercholesterolemia (HeFH) are at increased risk of atherosclerotic cardiovascular disease due to lifelong elevated levels of low-density lipoprotein cholesterol (LDL-C). Many patients with HeFH do not achieve guideline-recommended LDL-C goals with the currently available lipid-lowering therapies.

Objective

To evaluate the efficacy of enlicitide decanoate (an oral proprotein convertase subtilisin/kexin type 9 inhibitor) vs placebo in adults with HeFH requiring further lowering of LDL-C levels despite use of statin therapy. Design, Setting, and Participants This phase 3, randomized clinical trial included persons aged 18 years or older with HeFH currently using lipid-lowering therapy (taking at least a moderate- or high-intensity statin) and either an LDL-C level of 55 mg/dL or greater and a history of major atherosclerotic cardiovascular disease or an LDL-C level of 70 mg/dL or greater without a history of major atherosclerotic cardiovascular disease. The trial was conducted at 59 sites across 17 countries; the first participant was screened on August 8, 2023, and the last follow-up visit occurred on April 7, 2025.

Interventions

Participants were randomized (2:1) to 20 mg of enlicitide (n = 202) or placebo (n = 101) once daily for 52 weeks. Main Outcomes and Measures The primary outcome was the mean percentage change in LDL-C level at week 24. The secondary outcomes included the mean percentage change in LDL-C level at week 52, the mean percentage change at week 24 in levels of non–high-density lipoprotein cholesterol (non–HDL-C) and apolipoprotein B, and the median percentage change at week 24 in lipoprotein(a).

Results

Of the 303 participants (mean age, 52.4 [SD, 13.5] years; 51% were female) randomized, 293 (96.7%) completed the trial. The mean LDL-C level was 119.0 mg/dL (SD, 41.0 mg/dL) at baseline, all had statin current use (81.5% were taking a high-intensity statin), and 64.4% were taking ezetimibe. The mean percentage change in LDL-C level at week 24 was −58.2% in the enlicitide group vs 2.6% in the placebo group (between-group difference, −59.4% [95% CI, −65.6% to −53.2%]; P < .001). The mean percentage change in LDL-C level at week 52 was −55.3% in the enlicitide group vs 8.7% in the placebo group (between-group difference, −61.5% [95% CI, −69.4% to −53.7%]; P < .001). At week 24, the mean percentage change in non–HDL-C level was −52.3% in the enlicitide group vs 2.1% in the placebo group (between-group difference, −53.0% [95% CI, −58.5% to −47.4%]; P < .001), the mean percentage change in apolipoprotein B level was −48.2% vs 1.8%, respectively (between-group difference, −49.1% [95% CI, −54.0% to −44.3%]; P < .001), and the median percentage change in lipoprotein(a) level was −24.7% vs −1.6% (between-group difference, −27.5% [95% CI, −34.3% to −20.6%]; P < .001). The incidence of adverse events, serious adverse events, and study discontinuation due to adverse events was similar between groups.

Conclusions

Among adults with HeFH, treatment with enlicitide was well tolerated and significantly reduced levels of LDL-C, apolipoprotein B, non–HDL-C, and lipoprotein(a). Trial Registration ClinicalTrials.gov Identifier: NCT05952869

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anticholesteremic AgentsHyperlipoproteinemia Type IIPCSK9 InhibitorsAdultAgedFemaleHumansMaleMiddle AgedAdministration, OralApolipoproteins BCholesterol, LDLDouble-Blind MethodHeterozygoteHydroxymethylglutaryl-CoA Reductase InhibitorsLipoprotein(a)Proprotein Convertase 9Treatment Outcome

Substanzen

Anticholesteremic AgentsApolipoproteins BCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsLipoprotein(a)PCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9

Autor:innen und Institutionen

  • Texas Heart Institute, Baylor College of Medicine, Houston, Texas.
  • Merck & Co, Inc, Rahway, New Jersey.
  • Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.
  • Department of Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas.
  • Lipid Clinic, Oslo University Hospital, Oslo, Norway.
  • NZ Clinical Research, Christchurch, New Zealand.

Zitieren

APA

Ballantyne, C. M., Gellis, L., Tardif, J. C., Banka, P., Navar, A. M., Asprusten, E. A., Scott, R., Stroes, E. S. G., Froman, S., Mendizabal, G., Wang, F., & Catapano, A. L. (2026). Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia. JAMA, 335(2), 129. https://doi.org/10.1001/jama.2025.20620

Vancouver

Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, et al. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia. JAMA. 2026;335(2):129. doi:10.1001/jama.2025.20620

BibTeX
@article{Ballantyne2026,
  author = {Ballantyne, Christie M and Gellis, Laura and Tardif, Jean-Claude and Banka, Puja and Navar, Ann Marie and Asprusten, Emil Andreas and Scott, Russell and Stroes, Erik S G and Froman, Samar and Mendizabal, Geraldine and Wang, Fan and Catapano, Alberico L},
  title = {Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {2},
  pages = {129},
  doi = {10.1001/jama.2025.20620}
}
Kostenlos starten →